Alnylam Pharmaceuticals Stock News

Alnylam's fourth quarter product revenue was more or less as expected, with a faster/better-than-expected pace of switching between Onpattro and Amvuttra and further patient growth in Oxlumo and Givla

Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participat

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business

Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such

Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID

Alnylam's third quarter results were basically on target, with a stronger Amvuttra launch leading to more Onpattro switchovers, and some weakness in Givlaari and Oxlumo. There are still multiple credi

Alnylam missed Q3 revenue and EPS estimates, primarily due to lower-than-expected collaboration revenue. Amvuttra is off to a strong start in the United States with new patient starts doubling the pre

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.

Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corp

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.

Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.